Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 25, 2026.

Effects of diabetes on myocardial infarct size and cardioprotection by preconditioning and postconditioning

Takayuki Miki, Takahito Itoh, Daisuke Sunaga and 1 more

Cardiovascular Diabetology · 2012 · Review

doi:10.1186/1475-2840-11-67

Abstract

In spite of the current optimal therapy, the mortality of patients with ischemic heart disease (IHD) remains high, particularly in cases with diabetes mellitus (DM) as a co-morbidity. Myocardial infarct size is a major determinant of prognosis in IHD patients, and development of a novel strategy to limit infarction is of great clinical importance. Ischemic preconditioning (PC), postconditioning (PostC) and their mimetic agents have been shown to reduce infarct size in experiments using healthy animals. However, a variety of pharmacological agents have failed to demonstrate infarct size limitation in clinical trials. One of the possible reasons for the discrepancy between the results of animal experiments and clinical trials is that co-morbidities, including DM, modified myocardial responses to ischemia/reperfusion and to cardioprotective agents. Here we summarize observations of the effects of DM on myocardial infarct size and ischemic PC and PostC and discuss perspectives for protection of DM hearts.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 25, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Cardiovascular diseases are the leading cause of death, accounting for approximately 30% of all deaths worldwide. Among the various cardiovascular diseases, acute myocardial infarction (AMI) has a high rate of mortality, and infarct size is a primary determinant of prognosis in these patients. The only established and clinically approved method to limit infarct size is restoration of coronary blood flow by percutaneous coronary interventions (PCI), thrombolytic agents or coronary bypass surgery. However, our recent review of clinical infarct size data indicated that infarct size after current reperfusion therapy was larger than 75% of the area at risk and larger than 20% of the left ventricle in one fourth of AMI patients. Lack of substantial myocardial salvage in those patients cannot be simply attributable to long symptom-to-reperfusion time, and involvement of reperfusion injury is also possible. Nevertheless, significant percentages of AMI patients suffer from insufficient cardiac function and have a poor prognosis even after successful restoration of coronary flow. Therefore, the establishment of a novel strategy to limit the extent of infarction during ischemia/reperfusion is of great clinical importance.

As a cardioprotective strategy, ischemic preconditioning (PC) has received much attention for its potent infarct size-limiting effect since its first report by Murry et al. in 1986. Zhao et al. found that “conditioning” with repetitive ischemia/reperfusion at the time of reperfusion also affords protection and named the phenomenon ischemic postconditioning (PostC). Laboratory investigations to date have clarified outlines of the intracellular mechanisms of PC and PostC. In addition, several agents targeting signaling relevant to PC and PostC have been shown to act as PostC mimetics. However, clinical benefits of PC, PostC and their mimetics were not always demonstrated in clinical trials. The discrepancy between results of animal studies and clinical trials may be explained by notable differences between animal models of AMI and AMI in humans. First, there are species differences in regulatory mechanisms of cardiomyocytes such as contribution of sarcolemmal Ca2+ ATPase to overall Ca2+ handling. Second, the timing of administration of the test agent was not exactly the same in the positive animal studies and negative clinical trials. Third, most of the patients with AMI were pretreated with pharmacological agents for their co-morbidities at the onset of AMI, whereas animals were untreated, except for anesthetic agents, before AMI in most of the previous studies. Pharmacological agents used for treatment of hypertension, dyslipidemia and/or diabetes mellitus (DM) potentially modify intracellular signaling relevant to cytoprotection and thus myocardial responses to PC, Post and PC mimetics. Fourth, AMI patients recruited to clinical studies were generally old and had concomitant diseases, whereas relatively young and healthy animals were used in most of the previous animal studies. Aging and co-morbidities have been shown to modify or even abrogate the infarct size-limiting effects of interventions in animal experiments and thus possibly underlie the negative results in clinical trials.

Of morbidities that potentially compromise the protective mechanisms of the heart, DM appears primarily important to study today. The number of patients with DM has been increasing worldwide in the past two decades, and these patients are predisposed to serious cardiovascular morbidity and mortality. Despite recent progress in coronary intervention strategies, DM is associated with higher mortality after AMI due to more extensive atherosclerotic lesions and also hypertrophied and dysfunctional left ventricle. Interestingly, Lamblin et al. recently showed that rates of cardiovascular death and heart failure after the first AMI were higher in DM patients than in non-DM patients, though ventricular function and remodeling were comparable in the two groups. The increased mortality after AMI in DM patients is unlikely to be prevented simply by improvement of glycemic control, since intensive glycemic controls failed to reduce cardiovascular events as well as mortality rate in DM patients in recent large-scale clinical trials. Hence, we need novel strategies for protecting DM patients with coronary artery diseases from excessive myocardial ischemia-reperfusion injury. To gain an insight into a novel strategy, we thoroughly review reported effects of DM on myocardial infarct size and on protective mechanisms against infarction and discuss future perspectives in this article. Our discussion on pathophysiology and clinical approach to diabetic cardiomyopathy was recently published elsewhere.

Changes in myocardial susceptibility to infarction by DM

Clinical studies showed that DM increased the susceptibility of the myocardium to ischemia/reperfusion injury. However, results of infarct size studies in diabetic animal models were contradictory (Tables 1 and 2), and the reason for the inconsistency remains unclear.

Multiple mechanisms are involved in cardiomyocyte necrosis induced by ischemia/reperfusion. Depletion of intracellular ATP, intracellular overloading with Na+ and Ca2+, and increased fragility of the cell membrane are major changes during ischemia relevant to cell necrosis. Accumulating evidence supports the notion that the mitochondrial permeability transition pore (mPTP) is primed during ischemia and is opened by Ca2+ overload and burst of reactive oxygen species at the time of reperfusion, leading to irreversible loss of mitochondrial functions and cell necrosis. Theoretically, modification of ischemia-induced changes or reperfusion-induced opening of the mPTP should underlie the change in myocardial susceptibility to infarction in DM hearts. However, such modification has not been understood well.

Experimental studies

Infarct size in animal models of DM was larger or smaller than or similar to, depending on reports, that in non-diabetic controls (Table 1). As shown in Table 1, there were numerous differences in experimental preparations and protocols, and a single factor cannot entirely explain the discrepancy in the effects of DM on infarct size. Duration of the diabetic state and plasma level of insulin (i.e., type 1 DM vs. type 2 DM) appear to influence myocardial tolerance against infarction. In a study by Ravingerová et al., infarct size after 30-min ischemia was smaller in diabetic rat hearts at 1 week after streptozotocin (STZ) injection than in controls, but this infarct size limitation was not detected 8 weeks later. Two other studies have also shown that resistance of diabetic hearts to ischemia/reperfusion injury was detectable at the early phase of DM and disappeared later. However, enlargement of infarct size was observed as early as 8 days after STZ injection, indicating that duration of DM is not the only factor responsible for inconsistent effects of DM on infarct size.

Difference in metabolic profiles associated with DM (i.e., presence or absence of hyperinsulinemia and types of dyslipidemia) may also be responsible for different changes in infarct size in DM animals. With a few exceptions, DM models with obesity and hyperinsulinemia showed increased myocardial susceptibility to ischemia/reperfusion-induced necrosis. In contrast, high glucose level induced simply by glucose or dextrose infusion did not affect infarct size in the majority of studies, including two recent studies (Table 2).

Clinical studies

Increased myocardial susceptibility to infarction in DM patients was indicated by two clinical studies: infarct size determined by SPECT imaging after reperfusion therapy was larger by 30 ~ 70% in DM patients than in non-DM patients. The change in myocardial tolerance to infarction is consistent with worse short- and long-term prognosis after AMI in DM patients. Of particular relevance, Haffner et al. showed that cardiovascular event risk in DM patients without prior myocardial infarction was comparable to the risk in non-diabetic patients with prior myocardial infarction. However, the untoward effects of DM on prognosis after AMI cannot be explained solely by increased myocardial vulnerability to ischemia/reperfusion injury, since the risk of heart failure and death was significantly higher in DM patients than in non-DM patients with comparable infarct sizes and left ventricular ejection fractions. Myopathic changes (“diabetic cardiomyopathy”), impaired collateral recruitment, microcirculatory abnormalities, and underuse of evidence-based therapies are possible explanations, in addition to increased susceptibility to infarction, for detrimental prognosis after AMI in DM patients.

Defects in intracellular protective signaling in DM hearts

DM is one of the co-morbidities that potentially modify myocardial response to protective interventions, including PC and PostC. A number of studies have been carried out to determine the efficacy of ischemic PC and PostC for protecting the myocardium in animal models of DM (Tables 3 and 4) and diabetic patients (Table 5). The majority of those studies showed that DM interferes with protective mechanisms of cardioprotective interventions. Myocardial protection by PC and PostC is achieved by activation of multiple protective signaling pathways that appear to converge to inhibit mPTP opening upon reperfusion via phosphorylation of glycogen synthase kinase-3β (GSK-3β) at Ser9, and DM-induced defects in the protective signaling may be different depending on the model and/or phase of DM.

Experimental studies

With a few exceptions, previous studies demonstrated that cardioprotection achieved by ischemic PC or PostC is impaired in DM: the infarct size-limiting effect was lost or required extra cycles of ischemia/reperfusion in experimental diabetes (Table 3). Tsang et al. reported that one, two and three cycles of ischemic PC significantly reduced infarct size in normal rats; however, three cycles of ischemic PC were required to limit infarct size in diabetic Goto-Kakizaki rats. Their findings suggested that the threshold for PC protection is increased in the diabetic myocardium. Liu et al. were the first to examine the effects of DM on PC and they reported preservation of PC protection in STZ-induced DM. However, since they used a PC protocol with multiple cycles of ischemia/reperfusion only, the change in the threshold for inducing PC protection might have been missed in their study. In fact, impairment of PC by DM has been observed in multiple species (rats, rabbits and dogs) and different models of DM (STZ-induced type 1 DM and genetic models of type 2 DM). Mimetics of ischemic PC and PostC (diazoxide, erythropoietin, [D-Ala2, D-Leu5-enkephalin acetate [DADLE] and isoflurane) were also ineffective for limitation of infarct size in DM hearts, confirming that DM impairs intracellular signaling mechanisms relevant to myocardial protection.

Several steps in cytoprotective signaling have been found to be disrupted by DM in the heart. Blocked or attenuated signaling via phosphoinsitide-3 kinase (PI3K)-Akt, extracellular signal-regulated kinase (ERK) and/or signal transducer and activator of transcription-3 (STAT3) pathways was detected in association with loss or reduced efficiency of PC in protection against infarction. Our recent studies have shown that phosphorylation of Jak2, being upstream of PI3K-Akt signaling, is inhibited by enhanced calcineurin activity and that phosphorylation of GSK-3β by ERK is lost by an endoplasmic reticulum stress-dependent mechanism in OLETF, a rat model of obese type 2 DM. Furthermore, protein level of active GSK-3β, a pro-necrotic and pro-apoptotic kinase, was increased in mitochondria, leading to reduction in the threshold for mPTP opening in response to Ca2+ overload. On the other hand, a protective mechanism downstream of GSK-3β phosphorylation appears to be intact in diabetic hearts, since direct pharmacological inhibitors of GSK-3β limited infarct size in diabetic hearts as in non-diabetic animals.

An important and clinically relevant issue is whether hyperglycemia per se is responsible for disruption of protective signaling in PC and PostC. Acute hyperglycemia induced by dextrose infusion attenuated infarct size limitation by ischemic PC, a mitochondrial ATP-sensitive K+ channel (KATP channel) opener and anesthetic agents (Table 4). These results indicate a primary role of hyperglycemia in impairment of protective signaling. Interestingly, Przyklenk et al. reported that the cardioprotective effect of ischemic PostC was re-established in STZ-induced diabetic mice by pancreas islet cell transplantation. Transplantation of islet cells in diabetic mice normalized both blood glucose level and free fatty acid level and cellular signaling, such as ERK phosphorylation, activated by ischemic PostC. Since dyslipidemia was also shown to attenuate the infarct size-limiting effect of ischemic PC, restoration of myocardial response to PostC in the diabetic heart by islet cell transplantation might be achieved by normalization of both plasma glucose level and lipid profile. Nevertheless, circumstantial evidence in animal experiments supports the notion that normalization of the metabolic profile restores protective signaling mechanisms in the DM heart.

Clinical studies on PC

PC protection in human hearts has been demonstrated by results of in vitro experiments using human ventricular myocytes and atrial trabeculae and by detailed analyses of myocardial responses in patients with naturally occurring ischemic syndromes. Since ischemic PC and PC-like phenomena in human hearts have been recently reviewed elsewhere, we briefly summarize the results that are relevant to the effects of DM on ischemic PC. As for PC-like effects of preinfarct angina, different groups reported that pre-infarct angina was associated with smaller infarct size determined by creatine kinase (CK) release, improved left ventricular function and reduced mortality. Furthermore, in overall analysis of AMI patients, angina before AMI was associated with better long-term prognosis. However, in patients with DM, beneficial effects of pre-infarct angina were not detected. Ishihara et al. showed that CK release and recovery of cardiac function and in-hospital mortality after AMI were similar in DM patients with and without pre-infarct angina. DM-induced impairment of ischemic PC protection in human hearts has also been indicated by studies in which myocardial injury was assessed during angioplasty and during a treadmill exercise test by use of electrocardiography.

Direct evidence for diabetes-induced loss of ischemic PC protection in the human myocardium was provided by an in vitro experiment using atrial trabeculae obtained at open heart surgery. CK release and contractile dysfunction after hypoxia/reoxygenation in vitro was significantly suppressed by PC in trabeculae from non-diabetic patients but not in trabeculae from diabetic patients.

Clinical studies on PostC

In contrast to PC, PostC or administration of its mimetic at the time of reperfusion is clinically feasible. In 2005, Staat et al. translated for the first time the concept of ischemic PostC into the clinical setting. PostC with four cycles of 1-min inflation and 1-min deflation before full reperfusion successfully reduced CK release in a small and selected cohort of patients with AMI. Efficacy of ischemic PostC in patients with AMI was subsequently confirmed in a number of small-scale studies, using as endpoints cardiac biomarkers, ECG ST-segment resolution, and anatomic infarct size (Table 5). However, three recent studies failed to show protection by ischemic PostC in terms of CK and troponin release, LV function or infarct size that was determined by delayed enhancement magnetic resonance imaging (MRI). The reasons for the discrepant results remain uncertain, but there are some possibilities: differences in the protocols of ischemic PostC, presence of co-morbidities and use of different pharmacological agents for the co-morbidities.

In the PostC protocol, duration from reperfusion to the first re-occlusion and number of re-occlusions have been shown to influence the infarct size-limiting effects of PostC in animal models of AMI. Retrospective analyses by Darling et al. and Wang et al. suggest that larger numbers of balloon inflations–deflations were associated with greater protection in patients with AMI. However, an appropriate algorithm of PostC stimulus to maximally protect the human myocardium has not been established. In addition, protection by PostC in animal models of AMI is attenuated with aging and presence of co-morbidities, such as DM, hypertension and hypercholesterolemia. Although characteristics of patients, such as age and prevalence of DM, seem to be similar in the human studies (Table 5), difference in durations of the co-morbidities might have been involved in the different outcomes. Nevertheless, the effect of DM on protection afforded by PostC has not been specifically examined in clinical studies.

The effects of pharmacological PostC (i.e., administration of pharmacological agents at reperfusion) on myocardial injury have been examined in a number of clinical trials. Results of the trials are a mixture of positive and negative results, and the reason for the discrepancy remains unknown. Adenosine infusion limited infarct size, but neither the death rate during 6-month follow-up nor the rate of re-hospitalization for heart failure were reduced by the adenosine treatment. A post hoc analysis suggested that only patients with early reperfusion therapy received clinical benefits of adenosine, such as a reduction in death or heart failure. In the J-WIND trial, the effects of nicorandil and ANP on infarct size in different study arms were examined. Administration of nicorandil failed to significantly limit infarct size, though recombinant ANP infusion was shown to induce a small but significant reduction in infarct size. The results of studies on the effect of erythropoietin administered at reperfusion were discrepant. Taken together, there are a few promising agent for infarct size limitation in AMI patients, but none of their effects has been unequivocally demonstrated to be sufficient for improving prognosis.

Effects of anti-diabetic medications on AMI in diabetic patients

Possible adverse effects of sulfonylureas on cardiac events in DM patients have been debated for decades, and recent studies have indicated that cardiovascular risk was significantly higher in DM patients treated with sulfonylureas than in those who received metformin monotherapy. Sulphonylureas have been shown to inhibit protection of PC and PostC by blocking the ATP-sensitive K+ channel (KATP channel) in cardiomyocytes, raising concern that such actions of sulphonylureas may be detrimental at the time of AMI in DM patients. However, the effects on PC and PostC are actually not uniform across sulfonylureas. Glibenclamide, a non-specific blocker of the KATP channel, abrogated the infarct size-limiting effect of PC and PostC in non-diabetic animals. In contrast, glimepiride, a second-generation sulfonylurea, did not block the protective effect of PC in the animal myocardium or human myocardium, presumably because this agent has few cardiac actions. In addition, glimepiride was shown to have a PostC-mimetic action by activation of PI3K/Akt in the rabbit myocardium. However, the effects of sulfonylureas on PC in diabetes have been tested in only a few studies, since PC and PostC failed to limit infarction in most of the DM models. Interestingly, Nieszner et al. reported that infarct-sparing effect of PC in alloxan-treated diabetic rabbits was restored by pretreatment with a low dose, but not a high dose, of glibenclamide. The mechanism by which glibenclamide restored myocardial response to PC in the DM rabbit is unclear. However, beneficial effects of glycemic control, possibly on PI3K/Akt signaling, might have overwhelmed the effect of partial inhibition of cardiac KATP channels when an appropriate dose of glibenclamide was selected.

Metformin is an insulin-sensitizing agent that reduces hepatic glucose output and increases the uptake of glucose in peripheral tissues, including the skeletal muscle. In non-diabetic animals, metformin reduced infarct size by activation of AMP-activated protein kinase and/or Akt. However, whether metformin is additive to ischemic PC or PostC has not been examined. Infarct size-limiting effect of metformin in diabetic animals was controversial: there are two positive reports and one negative report.

Thiazolidinediones (pioglitazone, rosiglitazone) administered before ischemia reduced infarct size in both normal and diabetic animals. However, the impact of the cardioprotective effect of thiazolidinediones on clinical outcome is unclear, since the effects of pioglitazone and rosiglitazone on risk of cardiovascular events appear discrepant.

In the past few years, growing evidence has demonstrated cardiovascular effects of incretin-based therapy using glucagon-like peptide-1 (GLP-1) receptor agonists and inhibitors of dipeptidyl peptidase-4 (DPP-4). However, the effects of GLP-1 receptor agonists or DPP-4 inhibitors on ischemia/reperfusion injury have not been examined in diabetic animals except for a study by Huisamen et al. They reported that enlargement of infarct size in obese pre-diabetic rats was reduced by treatment with a DPP-4 inhibitor for 4 weeks. Further investigation is necessary for clarifying the effects of GLP-1 analogues and DPP-4 inhibitors on intracellular protective signaling and its modification by DM, though there are a number of on-going large-scale clinical trials to test the effects of incretin-based therapy on cardiovascular outcomes.

Conclusions and perspectives

DM potentially increases myocardial susceptibility to ischemia/reperfusion injury, though it cannot be explained by chronic hyperglycemia alone. DM also modifies myocardial responses to ischemic and pharmacological PC and PostC by disruption of intracellular signaling responsible for enhancement of resistance to cell death. These alterations in the diabetic heart appear to underlie the poor prognosis of DM patients after AMI. In addition, a defect of the protective mechanisms caused by aging, DM and possibly other co-morbidities is one of possible reasons why infarct size-limiting effects of agents in animal studies could not have been translated into AMI patients.

Analyses of modifications of cytoprotective signaling by DM, heart failure, dyslipidemia and hypertension generally showed that defects in the signaling by the pathological factors are upstream of a step of GSK-3β phosphorylation and mPTP regulation. Hence, a reasonable approach to protect the heart in DM patients is manipulation of protective mechanisms at the level of GSK-3β or mPTP. Blockade of mPTP opening by cyclosporine A at the time of reperfusion is one such approach, and its effect was first examined in 58 AMI patients. Infarct size determined by MRI at 5 days after AMI was significantly limited by cyclosporine A and the beneficial effects persisted until 6 month after AMI. The results are very promising and support the feasibility of a strategy for cardioprotection targeting the mPTP. However, how DM modifies the mPTP regulation and how we can suppress opening of the mPTP at the time of reperfusion need to be further investigated for devising a novel therapy for cardioprotection in DM patients.

Abbreviations

AMI: Acute myocardial infarction; CK: Creatine kinase; DADLE: [D-Ala2,D-Leu5]-enkephalin acetate; DM: Diabetes mellitus; DPP-4: Dipeptidyl peptidase-4; ERK: Extracellular signal-regulated kinase; GLP-1: Glucagon-like peptide-1; GSK-3β: Glycogen synthase kinase-3β; IHD: Ischemic heart disease; KATP channel: ATP-sensitive K+ channel; MPTP: Mitochondrial permeability transition pore; MRI: Magnetic resonance imaging; PC: Preconditioning; PCI: Percutaneous coronary interventions; PostC: Postconditioning; PI3K: Phosphoinositide-3 kinase; PKC: Protein kinase C; STZ: Streptozotocin.

Competing interests

TaM has received research funding from Daiichi-Sankyo, Japan, Eisai, Japan, and Pfizer, Japan. TI and DS have no conflicts of interest or financial ties to disclose. TeM has received research funding from Takeda Pharmaceuticals, Japan, Novartis, Japan, Chugai Pharmaceutical, Japan, and Astellas Pharma, Japan.

Authors' contributions

TaM collected and arranged the data in sequence, drafted and correspond the manuscript. TI and DS contributed to collection and analysis of the data. TeM contributed to analysis and interpretation of data and revision. All authors have read and approved the final manuscript.

References 109

  1. 1.

    Roger VL Go AS Lloyd-Jones DM Benjamin EJ Berry JD Borden WB Bravata DM Dai S Ford ES Fox CS Heart disease and stroke statistics–2012 update: a report from the American Heart AssociationCirculation2012 1251e2e220

    Not in our library10.1161/cir.0b013e31823ac046

  2. 2.

    Miura T Miki T Limitation of myocardial infarct size in the clinical setting: current status and challenges in translating animal experiments into clinical therapyBasic Res Cardiol2008 1036501513

    Not in our library10.1007/s00395-008-0743-y

  3. 3.

    Yellon DM Hausenloy DJ Myocardial reperfusion injuryN Eng J Med2007 3571111211135

    Not in our library10.1056/nejmra071667

  4. 4.

    Murry CE Jennings RB Reimer KA Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardiumCirculation1986 74511241136

    Not in our library10.1161/01.cir.74.5.1124

  5. 5.

    Zhao ZQ Corvera JS Halkos ME Kerendi F Wang NP Guyton RA Vinten-Johansen J Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioningAm J Physiol Heart Circ Physiol2003 2852H579H588

    Not in our library10.1152/ajpheart.01064.2002

  6. 6.

    Ferdinandy P Schulz R Baxter GF Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioningPharmacol Rev2007 594418458

    Not in our library10.1124/pr.107.06002

  7. 7.

    Yellon DM Downey JM Preconditioning the myocardium: from cellular physiology to clinical cardiologyPhysiol Rev2003 83411131151

    Not in our library10.1152/physrev.00009.2003

  8. 8.

    Ovize M Baxter GF Di Lisa F Ferdinandy P Garcia-Dorado D Hausenloy DJ Heusch G Vinten-Johansen J Yellon DM Schulz R Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of CardiologyCardiovasc Res2010 873406423

    Not in our library10.1093/cvr/cvq129

  9. 9.

    Sanada S Komuro I Kitakaze M Pathophysiology of myocardial reperfusion injury: preconditioning, postconditioning, and translational aspects of protective measuresAm J Physiol Heart Circ Physiol2011 3015H1723H1741

    Not in our library10.1152/ajpheart.00553.2011

  10. 10.

    Bolli R Becker L Gross G Mentzer R Balshaw D Lathrop DA Myocardial protection at a crossroads: the need for translation into clinical therapyCirc Res2004 952125134

    Not in our library10.1161/01.res.0000137171.97172.d7

  11. 11.

    Przyklenk K Efficacy of cardioprotective 'conditioning' strategies in aging and diabetic cohorts: the co-morbidity conundrumDrugs Aging2011 285331343

    Not in our library10.2165/11587190-000000000-00000

  12. 12.

    Danaei G Finucane MM Lu Y Singh GM Cowan MJ Paciorek CJ Farzadfar JK Farzadfar F Khang YH Stevens GA National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participantsLancet2011 37897853140

    Not in our library10.1016/s0140-6736(11)60679-x

  13. 13.

    Kirtane AJ Ellis SG Dawkins KD Colombo A Grube E Popma JJ Fahy M Leon MB Moses JW Mehran R Paclitaxel-eluting coronary stents in patients with diabetes mellitus: pooled analysis from 5 randomized trialsJ Am Coll Cardiol2008 517708715

    Not in our library10.1016/j.jacc.2007.10.035

  14. 14.

    Cubbon RM Wheatcroft SB Grant PJ Gale CP Barth JH Sapsford RJ Ajjan R Kearney MT Hall AS Temporal trends in mortality of patients with diabetes mellitus suffering acute myocardial infarction: a comparison of over 3000 patients between 1995 and 2003Eur Heart J2007 285540545

    Not in our library10.1093/eurheartj/ehl510

  15. 15.

    Norhammar A Lindback J Ryden L Wallentin L Stenestrand U Improved but still high short- and long-term mortality rates after myocardial infarction in patients with diabetes mellitus: a time-trend report from the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care AdmissionHeart (British Cardiac Society)2007 931215771583

    Not in our library10.1136/hrt.2006.097956

  16. 16.

    Lamblin N Fertin M de Groote P Bauters C Cardiac remodeling and heart failure after a first anterior myocardial infarction in patients with diabetes mellitusJ Cardiovasc Med (Hagerstown)2012 136353359

    Not in our library10.2459/jcm.0b013e328353694b

  17. 17.

    Patel A MacMahon S Chalmers J Neal B Billot L Woodward M Marre M Cooper M Glasziou P Grobbee D Intensive blood glucose control and vascular outcomes in patients with type 2 diabetesN Eng J Med2008 3582425602572

    Not in our library10.1056/nejmoa0802987

  18. 18.

    Gerstein HC Miller ME Byington RP Goff DC Bigger JT Buse JB Cushman WC Genuth S Ismail-Beigi F Grimm RH Effects of intensive glucose lowering in type 2 diabetesN Eng J Med2008 3582425452559

    Not in our library10.1056/nejmoa0802743

  19. 19.

    Duckworth W Abraira C Moritz T Reda D Emanuele N Reaven PD Zieve FJ Marks J Davis SN Hayward R Glucose control and vascular complications in veterans with type 2 diabetesN Eng J Med2009 3602129139

    Not in our library10.1056/nejmoa0808431

  20. 20.
    Diabetic cardiomyopathy: pathophysiology and clinical features · 2012
    No notice
  21. 21.

    Marso SP Miller T Rutherford BD Gibbons RJ Qureshi M Kalynych A Turco M Schultheiss HP Mehran R Krucoff MW Comparison of myocardial reperfusion in patients undergoing percutaneous coronary intervention in ST-segment elevation acute myocardial infarction with versus without diabetes mellitus (from the EMERALD Trial)Am J Cardiol2007 1002206210

    Not in our library10.1016/j.amjcard.2007.02.080

  22. 22.

    Alegria JR Miller TD Gibbons RJ Yi QL Yusuf S Infarct size, ejection fraction, and mortality in diabetic patients with acute myocardial infarction treated with thrombolytic therapyAm Heart J2007 1544743750

    Not in our library10.1016/j.ahj.2007.06.020

  23. 23.

    Halestrap AP A pore way to die: the role of mitochondria in reperfusion injury and cardioprotectionBiochem Soc Trans2010 384841860

    Not in our library10.1042/bst0380841

  24. 24.

    Ravingerova T Neckar J Kolar F Ischemic tolerance of rat hearts in acute and chronic phases of experimental diabetesMol Cell Biochem2003 2491–2167174

    Not in our library10.1023/a:1024751109196

  25. 25.

    Xu G Takashi E Kudo M Ishiwata T Naito Z Contradictory effects of short- and long-term hyperglycemias on ischemic injury of myocardium via intracellular signaling pathwayExp Mol Pathol2004 7615765

    Not in our library10.1016/j.yexmp.2003.08.003

  26. 26.

    Ma G Al-Shabrawey M Johnson JA Datar R Tawfik HE Guo D Caldwell RB Caldwell RW Protection against myocardial ischemia/reperfusion injury by short-term diabetes: enhancement of VEGF formation, capillary density, and activation of cell survival signalingNaunyn Schmiedebergs Arch Pharmacol2006 3736415427

    Not in our library10.1007/s00210-006-0102-1

  27. 27.

    Marfella R D'Amico M Di Filippo C Piegari E Nappo F Esposito K Berrino L Rossi F Giugliano D Myocardial infarction in diabetic rats: role of hyperglycaemia on infarct size and early expression of hypoxia-inducible factor 1Diabetologia2002 45811721181

    Not in our library10.1007/s00125-002-0882-x

  28. 28.

    Marfella R Di Filippo C Esposito K Nappo F Piegari E Cuzzocrea S Berrino L Rossi F Giugliano D D'Amico M Absence of inducible nitric oxide synthase reduces myocardial damage during ischemia reperfusion in streptozotocin-induced hyperglycemic miceDiabetes2004 532454462

    Not in our library10.2337/diabetes.53.2.454

  29. 29.

    Di Filippo C Marfella R Cuzzocrea S Piegari E Petronella P Giugliano D Rossi F D'Amico M Hyperglycemia in streptozotocin-induced diabetic rat increases infarct size associated with low levels of myocardial HO-1 during ischemia/reperfusionDiabetes2005 543803810

    Not in our library10.2337/diabetes.54.3.803

  30. 30.

    Kristiansen SB Lofgren B Nielsen JM Stottrup NB Buhl ES Nielsen-Kudsk JE Nielsen TT Rungby J Flyvbjerg A Botker HE Comparison of two sulfonylureas with high and low myocardial K(ATP) channel affinity on myocardial infarct size and metabolism in a rat model of type 2 diabetesDiabetologia2011 542451458

    Not in our library10.1007/s00125-010-1970-y

  31. 31.

    Przyklenk K Maynard M Greiner DL Whittaker P Cardioprotection with postconditioning: loss of efficacy in murine models of type-2 and type-1 diabetesAntioxid Redox Signal2011 145781790

    Not in our library10.1089/ars.2010.3343

  32. 32.

    Jordan JE Simandle SA Tulbert CD Busija DW Miller AW Fructose-fed rats are protected against ischemia/reperfusion injuryJ Pharmacol Exp Ther2003 307310071011

    Not in our library10.1124/jpet.103.055970

  33. 33.

    Hotta H Miura T Miki T Togashi N Maeda T Kim SJ Tanno M Yano T Kuno A Itoh T Angiotensin II type 1 receptor-mediated upregulation of calcineurin activity underlies impairment of cardioprotective signaling in diabetic heartsCirc Res2010 1061129132

    Not in our library10.1161/circresaha.109.205385

  34. 34.

    Miki T Miura T Hotta H Tanno M Yano T Sato T Terashima Y Takada A Ishikawa S Shimamoto K Endoplasmic reticulum stress in diabetic hearts abolishes erythropoietin-induced myocardial protection by impairment of phospho-glycogen synthase kinase-3beta-mediated suppression of mitochondrial permeability transitionDiabetes2009 581228632872

    Not in our library10.2337/db09-0158

  35. 35.

    La Bonte LR Davis-Gorman G Stahl GL McDonagh PF Complement inhibition reduces injury in the type 2 diabetic heart following ischemia and reperfusionAm J Physiol Heart Circ Physiol2008 2943H1282H1290

    Not in our library10.1152/ajpheart.00843.2007

  36. 36.

    Bouhidel O Pons S Souktani R Zini R Berdeaux A Ghaleh B Myocardial ischemic postconditioning against ischemia-reperfusion is impaired in ob/ob miceAm J Physiol Heart Circ Physiol2008 2954H1580H1586

    Not in our library10.1152/ajpheart.00379.2008

  37. 37.

    Katakam PV Jordan JE Snipes JA Tulbert CD Miller AW Busija DW Myocardial preconditioning against ischemia-reperfusion injury is abolished in Zucker obese rats with insulin resistanceAm J Physiol Regul Integr Comp Physiol2007 2922R920R926

    Not in our library10.1152/ajpregu.00520.2006

  38. 38.

    Zhu SG Xi L Kukreja RC Type 2 diabetic Obese db/db mice are refractory to myocardial ischemic postconditioning In Vivo: potential role for Hsp20, F(1) -ATPase delta, and Echs1J Cell Mol Med2012 164950958

    Not in our library10.1111/j.1582-4934.2011.01376.x

  39. 39.

    Yue TL Bao W Gu JL Cui J Tao L Ma XL Ohlstein EH Jucker BM Rosiglitazone treatment in Zucker diabetic Fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injuryDiabetes2005 542554562

    Not in our library10.2337/diabetes.54.2.554

  40. 40.

    Calvert JW Gundewar S Jha S Greer JJ Bestermann WH Tian R Lefer DJ Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signalingDiabetes2008 573696705

    Not in our library10.2337/db07-1098

  41. 41.

    Honda T Kaikita K Tsujita K Hayasaki T Matsukawa M Fuchigami S Sugiyama S Sakashita N Ogawa H Takeya M Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates myocardial ischemia-reperfusion injury in mice with metabolic disordersJ Mol Cell Cardiol2008 445915926

    Not in our library10.1016/j.yjmcc.2008.03.004

  42. 42.

    Ichinomiya T Cho S Higashijima U Matsumoto S Maekawa T Sumikawa K High-dose fasudil preserves postconditioning against myocardial infarction under hyperglycemia in rats: role of mitochondrial KATP channelsCardiovasc Diabetol2012 1128

    Not in our library10.1186/1475-2840-11-28

  43. 43.

    Matsumoto S Cho S Tosaka S Higashijima U Maekawa T Hara T Sumikawa K Hyperglycemia raises the threshold of levosimendan- but not milrinone-induced postconditioning in rat heartsCardiovasc Diabetol2012 114

    Not in our library10.1186/1475-2840-11-4

  44. 44.

    Zuanetti G Latini R Maggioni AP Santoro L Franzosi MG Influence of diabetes on mortality in acute myocardial infarction: data from the GISSI-2 studyJ Am Coll Cardiol1993 22717881794

    Not in our library10.1016/0735-1097(93)90758-s

  45. 45.

    Chyun D Obata J Kling J Tocchi C In-hospital mortality after acute myocardial infarction in patients with diabetes mellitusAm J Crit Care2000 93168179

    Not in our library

  46. 46.

    Haffner SM Lehto S Ronnemaa T Pyorala K Laakso M Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarctionN Eng J Med1998 3394229234

    Not in our library10.1056/nejm199807233390404

  47. 47.

    Shah AM Uno H Kober L Velazquez EJ Maggioni AP MacDonald MR Petrie MC McMurray JJ Califf RM Pfeffer MA The inter-relationship of diabetes and left ventricular systolic function on outcome after high-risk myocardial infarctionEur J Heart Fail2010 121112291237

    Not in our library10.1093/eurjhf/hfq179

  48. 48.

    Tsang A Hausenloy DJ Mocanu MM Carr RD Yellon DM Preconditioning the diabetic heart: the importance of Akt phosphorylationDiabetes2005 54823602364

    Not in our library10.2337/diabetes.54.8.2360

  49. 49.

    Liu Y Thornton JD Cohen MV Downey JM Schaffer SW Streptozotocin-induced non-insulin-dependent diabetes protects the heart from infarctionCirculation1993 88312731278

    Not in our library10.1161/01.cir.88.3.1273

  50. 50.

    Kersten JR Toller WG Gross ER Pagel PS Warltier DC Diabetes abolishes ischemic preconditioning: role of glucose, insulin, and osmolalityAm J Physiol Heart Circ Physiol2000 2784H1218H1224

    Not in our library10.1152/ajpheart.2000.278.4.h1218

  51. 51.

    Nieszner E Posa I Kocsis E Pogatsa G Preda I Koltai MZ Influence of diabetic state and that of different sulfonylureas on the size of myocardial infarction with and without ischemic preconditioning in rabbitsExp Clin Endocrinol Diabetes2002 1105212218

    Not in our library10.1055/s-2002-33069

  52. 52.

    Kristiansen SB Lofgren B Stottrup NB Khatir D Nielsen-Kudsk JE Nielsen TT Botker HE Flyvbjerg A Ischaemic preconditioning does not protect the heart in obese and lean animal models of type 2 diabetesDiabetologia2004 471017161721

    Not in our library10.1007/s00125-004-1514-4

  53. 53.

    Galagudza MM Nekrasova MK Syrenskii AV Nifontov EM Resistance of the myocardium to ischemia and the efficacy of ischemic preconditioning in experimental diabetes mellitusNeurosci Behav Physiol2007 375489493

    Not in our library10.1007/s11055-007-0040-5

  54. 54.

    Yadav HN Singh M Sharma PL Involvement of GSK-3beta in attenuation of the cardioprotective effect of ischemic preconditioning in diabetic rat heartMol Cell Biochem2010 3431–27581

    Not in our library10.1007/s11010-010-0500-z

  55. 55.

    Kersten JR Montgomery MW Ghassemi T Gross ER Toller WG Pagel PS Warltier DC Diabetes and hyperglycemia impair activation of mitochondrial K(ATP) channelsAm J Physiol Heart Circ Physiol2001 2804H1744H1750

    Not in our library10.1152/ajpheart.2001.280.4.h1744

  56. 56.

    Matsumoto S Cho S Tosaka S Ureshino H Maekawa T Hara T Sumikawa K Pharmacological preconditioning in type 2 diabetic rat hearts: the roles of mitochondrial ATP-sensitive potassium channels and the phosphatidylinositol 3-kinase-Akt pathwayCardiovasc Drugs Ther2009 234263270

    Not in our library10.1007/s10557-009-6184-5

  57. 57.

    Gross ER Hsu AK Gross GJ Diabetes abolishes morphine-induced cardioprotection via multiple pathways upstream of glycogen synthase kinase-3betaDiabetes2007 561127136

    Not in our library10.2337/db06-0907

  58. 58.

    Ghaboura N Tamareille S Ducluzeau PH Grimaud L Loufrani L Croue A Tourmen Y Henrion D Furber A Prunier F Diabetes mellitus abrogates erythropoietin-induced cardioprotection against ischemic-reperfusion injury by alteration of the RISK/GSK-3beta signalingBasic Res Cardiol2011 1061147162

    Not in our library10.1007/s00395-010-0130-3

  59. 59.

    Drenger B Ostrovsky IA Barak M Nechemia-Arbely Y Ziv E Axelrod JH Diabetes blockade of sevoflurane postconditioning is not restored by insulin in the rat heart: phosphorylated signal transducer and activator of transcription 3- and phosphatidylinositol 3-kinase-mediated inhibitionAnesthesiology2011 114613641372

    Not in our library10.1097/aln.0b013e31820efafd

  60. 60.

    Ueda Y Kitakaze M Komamura K Minamino T Asanuma H Sato H Kuzuya T Takeda H Hori M Pravastatin restored the infarct size-limiting effect of ischemic preconditioning blunted by hypercholesterolemia in the rabbit model of myocardial infarctionJ Am Coll Cardiol1999 34721202125

    Not in our library10.1016/s0735-1097(99)00440-4

  61. 61.

    Ungi I Ungi T Ruzsa Z Nagy E Zimmermann Z Csont T Ferdinandy P Hypercholesterolemia attenuates the anti-ischemic effect of preconditioning during coronary angioplastyChest2005 128316231628

    Not in our library10.1378/chest.128.3.1623

  62. 62.

    Ikonomidis JS Tumiati LC Weisel RD Mickle DA Li RK Preconditioning human ventricular cardiomyocytes with brief periods of simulated ischaemiaCardiovasc Res1994 28812851291

    Not in our library10.1093/cvr/28.8.1285

  63. 63.

    Hassouna A Loubani M Matata BM Fowler A Standen NB Galinanes M Mitochondrial dysfunction as the cause of the failure to precondition the diabetic human myocardiumCardiovasc Res2006 692450458

    Not in our library10.1016/j.cardiores.2005.11.004

  64. 64.

    Kloner RA Shook T Przyklenk K Davis VG Junio L Matthews RV Burstein S Gibson M Poole WK Cannon CP Previous angina alters in-hospital outcome in TIMI 4. A clinical correlate to preconditioning?Circulation1995 9113745

    Not in our library10.1161/01.cir.91.1.37

  65. 65.

    Rezkalla SH Kloner RA Preconditioning and the human heartPanminerva Med2005 4726973

    Not in our library

  66. 66.

    Anzai T Yoshikawa T Asakura Y Abe S Akaishi M Mitamura H Handa S Ogawa S Preinfarction angina as a major predictor of left ventricular function and long-term prognosis after a first Q wave myocardial infarctionJ Am Coll Cardiol1995 262319327

    Not in our library10.1016/0735-1097(95)80002-x

  67. 67.

    Ishihara M Sato H Tateishi H Kawagoe T Shimatani Y Kurisu S Sakai K Ueda K Implications of prodromal angina pectoris in anterior wall acute myocardial infarction: acute angiographic findings and long-term prognosisJ Am Coll Cardiol1997 304970975

    Not in our library10.1016/s0735-1097(97)00238-6

  68. 68.

    Kloner RA Shook T Antman EM Cannon CP Przyklenk K Yoo K McCabe CH Braunwald E Prospective temporal analysis of the onset of preinfarction angina versus outcome: an ancillary study in TIMI-9BCirculation1998 971110421045

    Not in our library10.1161/01.cir.97.11.1042

  69. 69.

    Ishihara M Inoue I Kawagoe T Shimatani Y Kurisu S Nishioka K Kouno Y Umemura T Nakamura S Sato H Diabetes mellitus prevents ischemic preconditioning in patients with a first acute anterior wall myocardial infarctionJ Am Coll Cardiol2001 38410071011

    Not in our library10.1016/s0735-1097(01)01477-2

  70. 70.

    Lee TM Chou TF Impairment of myocardial protection in type 2 diabetic patientsJ Clin Endocrinol Metab2003 882531537

    Not in our library10.1210/jc.2002-020904

  71. 71.

    Ovunc K Effects of glibenclamide, a K(ATP) channel blocker, on warm-up phenomenon in type II diabetic patients with chronic stable angina pectorisClin Cardiol2000 237535539

    Not in our library10.1002/clc.4960230713

  72. 72.

    Sivaraman V Hausenloy DJ Wynne AM Yellon DM Preconditioning the diabetic human myocardiumJ Cell Mol Med2010 146B17401746

    Not in our library10.1111/j.1582-4934.2009.00796.x

  73. 73.

    Staat P Rioufol G Piot C Cottin Y Cung TT L'Huillier I Aupetit JF Bonnefoy E Finet G Andre-Fouet X Postconditioning the human heartCirculation2005 1121421432148

    Not in our library10.1161/circulationaha.105.558122

  74. 74.

    Freixa X Bellera N Ortiz-Perez JT Jimenez M Pare C Bosch X De Caralt TM Betriu A Masotti M Ischaemic postconditioning revisited: lack of effects on infarct size following primary percutaneous coronary interventionEur Heart J2012 331103112

    Not in our library10.1093/eurheartj/ehr297

  75. 75.

    Sorensson P Saleh N Bouvier F Bohm F Settergren M Caidahl K Tornvall P Arheden H Ryden L Pernow J Effect of postconditioning on infarct size in patients with ST elevation myocardial infarctionHeart (British Cardiac Society)2010 962117101715

    Not in our library10.1136/hrt.2010.199430

  76. 76.

    Tarantini G Favaretto E Marra MP Frigo AC Napodano M Cacciavillani L Giovagnoni A Renda P De Biasio V Plebani M Postconditioning during coronary angioplasty in acute myocardial infarction: the POST-AMI trialInt J Cardiol2012 Epub ahead of print

    Not in our library10.1016/j.ijcard.2012.03.136

  77. 77.

    Iliodromitis EK Georgiadis M Cohen MV Downey JM Bofilis E Kremastinos DT Protection from post-conditioning depends on the number of short ischemic insults in anesthetized pigsBasic Res Cardiol2006 1016502507

    Not in our library10.1007/s00395-006-0606-3

  78. 78.

    Chiari PC Bienengraeber MW Pagel PS Krolikowski JG Kersten JR Warltier DC Isoflurane protects against myocardial infarction during early reperfusion by activation of phosphatidylinositol-3-kinase signal transduction: evidence for anesthetic-induced postconditioning in rabbitsAnesthesiology2005 1021102109

    Not in our library10.1097/00000542-200501000-00018

  79. 79.

    Yang XM Proctor JB Cui L Krieg T Downey JM Cohen MV Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathwaysJ Am Coll Cardiol2004 44511031110

    Not in our library10.1016/j.jacc.2004.05.060

  80. 80.

    Darling CE Solari PB Smith CS Furman MI Przyklenk K 'Postconditioning' the human heart: multiple balloon inflations during primary angioplasty may confer cardioprotectionBasic Res Cardiol2007 1023274278

    Not in our library10.1007/s00395-007-0643-6

  81. 81.

    Wang G Zhang S Joggerst SJ McPherson J Zhao DX Effects of the number and interval of balloon inflations during primary PCI on the extent of myocardial injury in patients with STEMI: does postconditioning exist in real-world practice?J Invasive Cardiol2009 219451455

    Not in our library

  82. 82.

    Mahaffey KW Puma JA Barbagelata NA DiCarli MF Leesar MA Browne KF Eisenberg PR Bolli R Casas AC Molina-Viamonte V Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trialJ Am Coll Cardiol1999 34617111720

    Not in our library10.1016/s0735-1097(99)00418-0

  83. 83.

    Kopecky SL Aviles RJ Bell MR Lobl JK Tipping D Frommell G Ramsey K Holland AE Midei M Jain A A randomized, double-blinded, placebo-controlled, dose-ranging study measuring the effect of an adenosine agonist on infarct size reduction in patients undergoing primary percutaneous transluminal coronary angioplasty: the ADMIRE (AmP579 Delivery for Myocardial Infarction REduction) studyAm Heart J2003 1461146152

    Not in our library10.1016/s0002-8703(03)00172-8

  84. 84.

    Ross AM Gibbons RJ Stone GW Kloner RA Alexander RW A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II)J Am Coll Cardiol2005 451117751780

    Not in our library10.1016/j.jacc.2005.02.061

  85. 85.

    Kloner RA Forman MB Gibbons RJ Ross AM Alexander RW Stone GW Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trialEur Heart J2006 272024002405

    Not in our library10.1093/eurheartj/ehl094

  86. 86.

    Kitakaze M Asakura M Kim J Shintani Y Asanuma H Hamasaki T Seguchi O Myoishi M Minamino T Ohara T Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trialsLancet2007 370959714831493

    Not in our library10.1016/s0140-6736(07)61634-1

  87. 87.

    Ozawa T Toba K Suzuki H Kato K Iso Y Akutsu Y Kobayashi Y Takeyama Y Kobayashi N Yoshimura N Single-dose intravenous administration of recombinant human erythropoietin is a promising treatment for patients with acute myocardial infarction - randomized controlled pilot trial of EPO/AMI-1 studyCirc J2010 74714151423

    Not in our library10.1253/circj.cj-10-0109

  88. 88.

    Voors AA Belonje AM Zijlstra F Hillege HL Anker SD Slart RH Tio RA van 't Hof A Jukema JW Peels HO A single dose of erythropoietin in ST-elevation myocardial infarctionEur Heart J2010 312125932600

    Not in our library10.1093/eurheartj/ehq304

  89. 89.

    Najjar SS Rao SV Melloni C Raman SV Povsic TJ Melton L Barsness GW Prather K Heitner JF Kilaru R Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trialJAMA2011 3051818631872

    Not in our library10.1001/jama.2011.592

  90. 90.

    Ludman AJ Yellon DM Hasleton J Ariti C Babu GG Boston-Griffiths E Venugopal V Walker M Holdright D Swanton H Effect of erythropoietin as an adjunct to primary percutaneous coronary intervention: a randomised controlled clinical trialHeart (British Cardiac Society)2011 971915601565

    Not in our library10.1136/hrt.2011.223867

  91. 91.

    Ferrario M Arbustini E Massa M Rosti V Marziliano N Raineri C Campanelli R Bertoletti A De Ferrari GM Klersy C High-dose erythropoietin in patients with acute myocardial infarction: a pilot, randomised, placebo-controlled studyInt J Cardiol2011 1471124131

    Not in our library10.1016/j.ijcard.2009.10.028

  92. 92.

    Suh JW Chung WY Kim YS Kim KI Jeon EJ Cho YS Youn TJ Chae IH Kim CH Choi DJ The effect of intravenous administration of erythropoietin on the infarct size in primary percutaneous coronary interventionInt J Cardiol2011 1492216220

    Not in our library10.1016/j.ijcard.2010.02.002

  93. 93.

    Jorgensen CH Gislason GH Andersson C Ahlehoff O Charlot M Schramm TK Vaag A Abildstrom SZ Torp-Pedersen C Hansen PR Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention–a retrospective nationwide cohort studyCardiovasc Diabetol2010 954

    Not in our library10.1186/1475-2840-9-54

  94. 94.

    Schramm TK Gislason GH Vaag A Rasmussen JN Folke F Hansen ML Fosbol EL Kober L Norgaard ML Madsen M Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide studyEur Heart J2011 321519001908

    Not in our library10.1093/eurheartj/ehr077

  95. 95.

    Ye Y Perez-Polo JR Aguilar D Birnbaum Y The potential effects of anti-diabetic medications on myocardial ischemia-reperfusion injuryBasic Res Cardiol2011 1066925952

    Not in our library10.1007/s00395-011-0216-6

  96. 96.

    Klepzig H Kober G Matter C Luus H Schneider H Boedeker KH Kiowski W Amann FW Gruber D Harris S Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamideEur Heart J1999 206439446

    Not in our library10.1053/euhj.1998.1242

  97. 97.

    Mocanu MM Maddock HL Baxter GF Lawrence CL Standen NB Yellon DM Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxideCirculation2001 1032531113116

    Not in our library10.1161/01.cir.103.25.3111

  98. 98.

    Geisen K Vegh A Krause E Papp JG Cardiovascular effects of conventional sulfonylureas and glimepirideHormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme1996 289496507

    Not in our library10.1055/s-2007-979841

  99. 99.

    Nishida H Sato T Nomura M Miyazaki M Nakaya H Glimepiride treatment upon reperfusion limits infarct size via the phosphatidylinositol 3-kinase/Akt pathway in rabbit heartsJ Pharmacol Sci2009 1092251256

    Not in our library10.1254/jphs.08202fp

  100. 100.

    Bhamra GS Hausenloy DJ Davidson SM Carr RD Paiva M Wynne AM Mocanu MM Yellon DM Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore openingBasic Res Cardiol2008 1033274284

    Not in our library10.1007/s00395-007-0691-y

  101. 101.

    Kravchuk E Grineva E Bairamov A Galagudza M Vlasov T The effect of metformin on the myocardial tolerance to ischemia-reperfusion injury in the rat model of diabetes mellitus type IIExp Diabetes Res2011 2011907496

    Not in our library10.1155/2011/907496

  102. 102.

    Wilding JP PPAR agonists for the treatment of cardiovascular disease in patients with diabetesDiabetes Obes Metab2012 Epub ahead of print

    Not in our library10.1111/j.1463-1326.2012.01601.x

  103. 103.

    Chinda K Chattipakorn S Chattipakorn N Cardioprotective effects of incretin during ischaemia-reperfusionDiab Vasc Dis Res2012 Epub ahead of print

    Not in our library10.1177/1479164112440816

  104. 104.

    Yin M Sillje HH Meissner M van Gilst WH de Boer RA Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failureCardiovasc Diabetol2011 1085

    Not in our library10.1186/1475-2840-10-85

  105. 105.

    Chinda K Palee S Surinkaew S Phornphutkul M Chattipakorn S Chattipakorn N Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia-reperfusion injuryInt J Cardiol2012 Epub ahead of print

    Not in our library10.1016/j.ijcard.2012.01.011

  106. 106.

    Huisamen B Genis A Marais E Lochner A Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic ratsCardiovasc Drugs Ther2011 2511320

    Not in our library10.1007/s10557-010-6271-7

  107. 107.

    Ussher JR Drucker DJ Cardiovascular biology of the incretin systemEndocr Rev2012 332187215

    Not in our library10.1210/er.2011-1052

  108. 108.

    Piot C Croisille P Staat P Thibault H Rioufol G Mewton N Elbelghiti R Cung TT Bonnefoy E Angoulvant D Effect of cyclosporine on reperfusion injury in acute myocardial infarctionN Eng J Med2008 3595473481

    Not in our library10.1056/nejmoa071142

  109. 109.

    Mewton N Croisille P Gahide G Rioufol G Bonnefoy E Sanchez I Cung TT Sportouch C Angoulvant D Finet G Effect of cyclosporine on left ventricular remodeling after reperfused myocardial infarctionJ Am Coll Cardiol2010 551212001205

    Not in our library10.1016/j.jacc.2009.10.052

Cited by papers we hold 6

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.